Every 10-Q that Amesite Inc (AMST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AMST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMST filings page.
Amesite Inc. reported higher revenue but continued losses and liquidity pressures for the quarter ended March 31, 2026. Net revenue reached $83,332 for the quarter and $285,678 for the nine months, up sharply from the prior-year periods, reflecting a pivot toward AI-driven healthcare solutions such as its NurseMagic™ app.
The company still posted a net loss of $678,061 for the quarter and $2,052,875 for the nine months, with cash, cash equivalents and restricted cash of only $740,711 as of March 31, 2026. Management concludes that recurring losses and limited cash raise substantial doubt about Amesite’s ability to continue as a going concern.
On April 28, 2026, Amesite completed a registered direct offering and related private placements, issuing common stock and warrants for aggregate gross proceeds of about $2.6 million (approximately $2.2 million net), including insider participation. This capital raise is expected to fund working capital and also helped restore compliance with Nasdaq’s minimum stockholders’ equity requirement, though maintaining that compliance will depend on future results.
Amesite Inc. reports sharply higher revenue but continues to operate at a loss and faces going concern and listing risks. Net revenue for the six months ended December 31, 2025 rose to $202,346 from $24,010 a year earlier, with the quarter at $108,050 versus $12,760.
Cost-cutting reduced the six‑month net loss to about $1.37 million from $2.03 million, as general and administrative, technology, and sales and marketing expenses all declined. Cash, cash equivalents, and restricted cash fell to $1.27 million from $2.43 million at June 30, 2025, as operations used over $1.03 million of cash.
Management states there is substantial doubt about Amesite’s ability to continue as a going concern absent additional financing, and plans may include further common stock offerings. The company also discloses a Nasdaq deficiency notice for not meeting the $2.5 million stockholders’ equity requirement, with an extension to April 27, 2026 to regain compliance.
Amesite Inc. (AMST) reported first‑quarter results for the period ended September 30, 2025. Revenue was $94,296, up from $11,250 a year ago, as the company shifted focus toward healthcare with its NurseMagic product. Mix included B2B $70,244 (74%) and B2C $24,052 (26%). Operating discipline reduced expenses: G&A $547,060 (vs. $633,122), technology and content $102,888 (vs. $139,658), and sales and marketing $106,472 (vs. $165,814).
The company posted a net loss of $642,266 (vs. $908,045), with operating cash outflow of $415,765. Cash, cash equivalents, and restricted cash totaled $1,930,053 at quarter‑end, including a short‑term U.S. Treasury fund of approximately $1.65 million with 7‑day liquidity. Deferred revenue was $24,655. One customer represented 12% of revenue.
Management disclosed conditions that raise substantial doubt about Amesite’s ability to continue as a going concern. Plans contemplate financing transactions, which are subject to market conditions. Shares outstanding were 4,572,713 as of October 24, 2025.